These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37751103)

  • 1. NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
    Fetzko SL; Timothy LD; Parihar R
    Curr Hematol Malig Rep; 2023 Dec; 18(6):264-272. PubMed ID: 37751103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
    Lin C; Horwitz ME; Rein LAM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
    Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
    Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
    Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
    J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
    Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
    Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.